Intervention in HCM: patient selection, procedural approach and emerging techniques in alcohol septal ablation

Area of Science:

• Cardiology
• Interventional Cardiology
• Cardiac Surgery

Background:

• Hypertrophic cardiomyopathy (HCM) presents with diverse hypertrophy patterns, often leading to left ventricular outflow tract (LVOT) obstruction.
• Basal septal hypertrophy and systolic anterior motion (SAM) of the mitral valve are primary drivers of LVOT obstruction in HCM.
• LVOT obstruction in HCM significantly increases patient morbidity and mortality.

Purpose of the Study:

• To review the pathophysiology of LVOT obstruction in HCM.
• To summarize current methods and evidence for alcohol septal ablation (ASA) as a percutaneous septal reduction therapy.
• To explore emerging techniques for percutaneous septal reduction.

Main Methods:

• Review of relevant pathophysiology of HCM and LVOT obstruction.
• Summary of current alcohol septal ablation (ASA) techniques and procedural considerations.
• Analysis of existing evidence and outcomes data for ASA.
• Discussion of novel percutaneous septal reduction therapies.

Main Results:

• Alcohol septal ablation (ASA) effectively improves left ventricle hemodynamics and patient symptoms in HCM.
• The procedure involves targeted myocardial infarction via alcohol delivery to septal arteries.
• Pacemaker implantation is the most common complication, though ASA is successful in most patients.

Conclusions:

• ASA is a valuable percutaneous treatment for obstructive HCM, improving hemodynamics and symptoms.
• Careful patient selection, pre-procedural planning, and intra-procedural imaging are crucial for safe and effective ASA.
• While successful, ongoing research aims to refine ASA techniques and explore new percutaneous interventions for HCM.